Key Highlights
- SCTX shares closed up 0.92% at $29.74 at last closing, a small gain following its recent Nasdaq debut.
- Scribe is building genetic medicines with proprietary CRISPR-based tools, with a strategic focus on cardiometabolic disease.
- The company has reported initiating a first-in-human Phase 1 trial of STX-1150, an epigenetic silencing approach targeting PCSK9 to lower LDL cholesterol.
- Sell-side coverage initiated after the IPO has skewed positive, with a consensus leaning toward optimistic ratings.
A newly public CRISPR company edged higher in September 2026, and the move offered a reminder that fresh biotech listings rarely trade in a straight line. Scribe Therapeutics Inc (NASDAQ:SCTX), which debuted on the Nasdaq only weeks earlier, closed up 0.92% at $29.74 at last closing as Sell-Side analysts remained broadly constructive on the gene-editing developer.
Company and Latest Development
Scribe Therapeutics is a clinical-stage biotechnology company building genetic medicines with proprietary CRISPR-based tools, with a strategic focus on cardiometabolic disease. Its pipeline includes STX-1150, an epigenetic silencing approach aimed at PCSK9 to lower LDL cholesterol; STX-1200, a gene-editing program targeting elevated lipoprotein(a); and an earlier program, STX-1400. The company completed its initial public offering on July 24, 2026, and has reported initiating a first-in-human Phase 1 trial of STX-1150.
What Is Driving Attention Around SCTX?
The small gain did not track to a single, independently verifiable catalyst on the day. Recently listed biotechs commonly experience swings as lock-up dynamics, index positioning, and shifting risk appetite play out against limited trading history. Scribe reported second-quarter 2026 results on September 2, and the stock's move should be read against that recent disclosure and the broader tone in gene-editing equities.
Key Numbers and Company Position
Scribe carries a market Capitalization near $557 million. In its second-quarter 2026 report, the company recorded Revenue of about $1.92 million and a net loss per share of roughly $2.62, consistent with a clinical-stage developer generating limited collaboration revenue while investing heavily in research. Scribe employs approximately 89 people.
What Could Come Next?
The most meaningful catalysts ahead are clinical. Early data from the first-in-human STX-1150 study could provide the first human readout on Scribe's editing approach for LDL-C lowering, a closely watched cardiometabolic target.
Risks to Watch
Scribe faces the full slate of gene-editing risks: unproven long-term safety and durability, complex delivery challenges, and the possibility that early clinical data disappoint. As a pre-commercial company, it is dependent on continued financing, and future capital raises could dilute shareholders.
A First-in-Human Milestone Now Sets the Clock
Scribe Therapeutics remains an early-stage CRISPR story whose small September gain appeared rooted in normal post-IPO trading. With a first-in-human trial under way and cardiometabolic targets in focus, upcoming clinical readouts and financial updates are the developments investors may want to monitor most closely.






Please wait processing your request...